Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Vistagen Therapeutics (VTGN) FCF Margin (2016 - 2025)

Vistagen Therapeutics (VTGN) has disclosed FCF Margin for 13 consecutive years, with 5829.04% as the latest value for Q4 2025.

  • Quarterly FCF Margin fell 139186.0% to 5829.04% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 7639.11% through Dec 2025, down 175430.0% year-over-year, with the annual reading at 8662.55% for FY2025, 623379.0% down from the prior year.
  • FCF Margin hit 5829.04% in Q4 2025 for Vistagen Therapeutics, down from 5385.66% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 66413.33% in Q1 2025 to a low of 39456.92% in Q1 2022.
  • Historically, FCF Margin has averaged 2739.21% across 5 years, with a median of 4351.52% in 2024.
  • Biggest five-year swings in FCF Margin: tumbled -3825615bps in 2022 and later surged 7067919bps in 2025.
  • Year by year, FCF Margin stood at 3364.64% in 2021, then crashed by -61bps to 5407.67% in 2022, then surged by 79bps to 1159.37% in 2023, then plummeted by -283bps to 4437.18% in 2024, then tumbled by -31bps to 5829.04% in 2025.
  • Business Quant data shows FCF Margin for VTGN at 5829.04% in Q4 2025, 5385.66% in Q3 2025, and 7717.21% in Q2 2025.